Compare ARK Genomic Revolution ETF (ARKG) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Lockheed Martin Corporation — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Lockheed Martin Corporation trades at $527.92 (market cap $120.64B). The key difference: Lockheed Martin Corporation pays a 2.64% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Lockheed Martin Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | LMT | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $676.70 |
52-Week Low | $23.09 | $410.74 |
Market Cap | — | $120.64B |
Enterprise Value | — | $139.44B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Lockheed Martin (LMT) trades at $523.22, up 0.96% on the day, with a bearish technical signal despite recent positive momentum. The company reported $75.05B in 2025 revenue but missed Q1 2026 EPS estimates. Strong analyst consensus favors a buy rating with a $627.50 price target, supported by a $3.45 dividend and robust defense contracts, including a recent $3.5B naval acquisition and European missile production deals.
Outlook remains positive due to elevated defense spending and a $186.4B backlog, though risks include execution challenges and geopolitical volatility. The stock presents value with a P/E of 25.34 and high ROE of 67.64%, but investors should monitor earnings consistency and debt levels, which have risen to 36.26% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
